Squarepoint
VYNT

Squarepoint’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Squarepoint’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-130
Closed -$36K – 2283
2017
Q4 		$36K Buy
+130
New +$49.6K ﹤0.01% 2031
2017
Q1 		– Sell
-206
Closed -$42K – 2009
2016
Q4 		$42K Buy
+206
New +$46.8K ﹤0.01% 1707

Other funds holding VYNT

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DM
Diker Management New York $130M AUM 97.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Squarepoint's VYNT Position: Q1 2018 in Review

Squarepoint sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2018, closing a stake of 130 shares — an estimated $36K sold.

Squarepoint first reported a position in VYNT in Q4 2016 and held it in 2 quarters. The position peaked at $42K in Q4 2016. 26 funds tracked by Wall St. Rank hold VYNT as of Q1 2018.

  • Squarepoint reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Squarepoint sold 130 Vyant Bio, Inc. Common Stock shares in Q1 2018, an estimated $36K.
  • Squarepoint first reported a position in Vyant Bio, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Squarepoint's Vyant Bio, Inc. Common Stock position peaked at $42K in Q4 2016.
  • 26 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2018.

Based on Squarepoint's 13F filing for Q1 2018, filed 15 May 2018.